Dechert recently advised vTv Therapeutics on a purchase agreement for an $80 million private placement in public equity (PIPE) financing with healthcare institutional investors and the T1D Fund: A Breakthrough T1D Venture. The PIPE financing is subject to customary closing conditions and is expected to close on or around Sept. 3, 2025.
Investors in the financing include existing investors in the company: a life sciences-focused institutional investor, Samsara BioCapital and the T1D Fund. New investors include Trails Edge Capital Partners and Invus. TD Cowen and Evercore ISI are acting as lead placement agents for the PIPE financing.
The financing was designed to enable vTv to continue advancing the development of cadisegliatin, including the CATT1 trial, which is evaluating the potential of cadisegliatin to help reduce the frequency of level 2 and 3 hypoglycemic events and to improve glycemic control in people living with type 1 diabetes.
The Dechert team advising vTv was led by corporate and life sciences partner David S. Rosenthal and included associates Taylor Stevens, Anjanaye Jariwala and Abigail T. Ferraioli.
